The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.
 
Se-Hoon Lee
Honoraria - AstraZeneca; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca
 
June-Koo Lee
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
Research Funding - AstraZeneca
 
Dong-Wan Kim
No Relationships to Disclose
 
Jong-Mu Sun
Research Funding - AstraZeneca
 
Bhumsuk Keam
No Relationships to Disclose
 
Tae Min Kim
No Relationships to Disclose
 
Dae Seog Heo
No Relationships to Disclose
 
Jin Seok Ahn
Honoraria - AstraZeneca; Janssen; Lilly; Menarini; Roche
Consulting or Advisory Role - Boehringer Ingelheim
 
Yoon-La Choi
No Relationships to Disclose
 
Hae-Sook Min
No Relationships to Disclose
 
Yoon-Kyung Jeon
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca